Eric I. Rossman - Concepedia

Author

Eric I. Rossman

Temple University ORCID

Also Known As

E Rossman, E. I. Rossman, E. Rossman, E.I. Rossman, Eric I. Rossman, Eric I Rossman, Eric I. Rossman, Eric Rossman

Publications

891

Citations

H-Index

Concepts

All Affiliations

Temple University GlaxoSmithKline (United States)Eli Lilly (United States)Amgen (United States)Novartis (United States)

About

Eric I. Rossman is an author at Temple University specializing in medicine, cardiology, and electrophysiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	512
2	Public Health	3	3	132
3	Natural Sciences	1	1	36
4	Social Sciences	1	1	84
5	Anesthesia	1	1	23

Eric I. Rossman

Publications

787

Citations

H-Index

Page 1

	Year	Citations
Psychiatric Rehabilitation and Long-term Rehospitalization Rates: The Findings of Two Research Studies* Jessica H. Beard, Thomas J. Malamud, Eric I. Rossman Schizophrenia Bulletin Psychosocial RehabilitationResearch StudiesPsychiatryLong-term Rehospitalization RatesPsychiatric Evaluation	1978	112
Altered myocardial Ca2+cycling after left ventricular assist device support in the failing human heart Khuram W. Chaudhary, Eric I. Rossman, Valentino Piacentino, Journal of the American College of Cardiology Cardiac MuscleHeart FailureDevice TherapyCardiovascular DiseaseCardiac Mechanic	2004	93
Abnormal frequency-dependent responses represent the pathophysiologic signature of contractile failure in human myocardium Eric I. Rossman Journal of Molecular and Cellular Cardiology MechanobiologyCardiac MuscleCardiomyopathyHeart FailureCardiac Mechanic	2003	84
Blinded, Multicenter Evaluation of Drug-induced Changes in Contractility Using Human-induced Pluripotent Stem Cell-derived Cardiomyocytes Umber Saleem, Berend J. van Meer, Puspita Anggraini Katili, Toxicological Sciences	2020	68
The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium Brian D. Guth, Alan Y. Chiang, Jennifer Doyle, Journal of Pharmacological and Toxicological Methods	2015	54
Effects of Chronic Gap Junction Conduction–Enhancing Antiarrhythmic Peptide GAP-134 Administration on Experimental Atrial Fibrillation in Dogs Gabriel Laurent, Howard Leong‐Poi, Iqwal Mangat, Circulation Arrhythmia and Electrophysiology Electrophysiological EvaluationCardiovascular DiseaseMedicinePhysiologyExperimental Atrial Fibrillation	2009	54
The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model Eric I. Rossman, Kun Liu, Gwen A. Morgan, Journal of Pharmacology and Experimental Therapeutics	2009	53
Sex-based differences in myocardial contractile reserve Rebecca E. Petre, Michael P. Quaile, Eric I. Rossman, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology Cardiac MuscleHeart FailureCardiovascular FunctionKinesiologyBiomechanics	2006	47
Discovery of (2<i>S</i>,4<i>R</i>)-1-(2-Aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic Acid Hydrochloride (GAP-134)<sup>13</sup>, an Orally Active Small Molecule Gap-Junction Modifier for the Treatment of Atrial Fibrillation John A. Butera, Bjarne Due Larsen, James K. Hennan, Journal of Medicinal Chemistry -4-Benzamidopyrrolidine-2-carboxylic Acid HydrochloridePharmacotherapyCardiac ConductionChemical BiologyMolecular Pharmacology	2009	36
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19 Annie Delaunois, Matthew M. Abernathy, Warren D. Anderson, Clinical and Translational Science	2021	34

Page 1